 |
The Journal of Neuroscience, January 19, 2005, 25(3):629-636; doi:10.1523/JNEUROSCI.4337-04.2005
 Previous Article | Next Article 
Neurobiology of Disease
Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid 
Margaret M. Racke,1,2
Laura I. Boone,1,3
Deena L. Hepburn,1,2
Maia Parsadainian,9
Matthew T. Bryan,1,2
Daniel K. Ness,1,4
Kathy S. Piroozi,1,4
William H. Jordan,1,3
Donna D. Brown,1,4
Wherly P. Hoffman,1,5
David M. Holtzman,7,8,9,10
Kelly R. Bales,1,2
Bruce D. Gitter,1,2
Patrick C. May,1,2
Steven M. Paul,1,6 and
Ronald B. DeMattos1,2
1Lilly Research Laboratories, Eli Lilly and Company,2 Neuroscience Discovery Research, Departments of 3Pathology, 4Toxicology, and 5Statistics, Lilly Corporate Center, and 6Departments of Pharmacology, Toxicology, and Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46285, 7Center for the Study of Nervous System Injury, 8Alzheimer's Disease Research Center, and Departments of 9Neurology and 10Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri 63110
Passive immunization with an antibody directed against the N terminus of amyloid  (A) has recently been reported to exacerbate cerebral amyloid angiopathy (CAA)-related microhemorrhage in a transgenic animal model. Although the mechanism responsible for the deleterious interaction is unclear, a direct binding event may be required. We characterized the binding properties of several monoclonal anti-A antibodies to deposited A in brain parenchyma and CAA. Biochemical analyses demonstrated that the 3D6 and 10D5, two N-terminally directed antibodies, bound with high affinity to deposited forms of A, whereas 266, a central domain antibody, lacked affinity for deposited A. To determine whether 266 or 3D6 would exacerbate CAA-associated microhemorrhage, we treated aged PDAPP mice with either antibody for 6 weeks. We observed an increase in both the incidence and severity of CAA-associated microhemorrhage when PDAPP transgenic mice were treated with the N-terminally directed 3D6 antibody, whereas mice treated with 266 were unaffected. These results may have important implications for future immune-based therapeutic strategies for Alzheimer's disease.
Key words: amyloid; CAA; immunotherapy; microhemorrhage; Alzheimer's disease; transgenic
Received Oct 19, 2004;
revised November 22, 2004;
accepted November 29, 2004.
This article has been cited by other articles:
|
|
|
|
 
S. Schroeter, K. Khan, R. Barbour, M. Doan, M. Chen, T. Guido, D. Gill, G. Basi, D. Schenk, P. Seubert, et al.
Immunotherapy Reduces Vascular Amyloid-{beta} in PDAPP Mice
J. Neurosci.,
July 2, 2008;
28(27):
6787 - 6793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Petrushina, A. Ghochikyan, M. Mktrichyan, G. Mamikonyan, N. Movsesyan, H. Davtyan, A. Patel, E. Head, D. H. Cribbs, and M. G. Agadjanyan
Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric A{beta} Species in Amyloid Precursor Protein Transgenic Mice
J. Neurosci.,
November 14, 2007;
27(46):
12721 - 12731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Guo, T. E. Salt, V. Luong, N. Wood, W. Cheung, A. Maass, G. Ferrari, F. Russo-Marie, A. M. Sillito, M. E. Cheetham, et al.
Targeting amyloid-beta in glaucoma treatment
PNAS,
August 14, 2007;
104(33):
13444 - 13449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mamikonyan, M. Necula, M. Mkrtichyan, A. Ghochikyan, I. Petrushina, N. Movsesyan, E. Mina, A. Kiyatkin, C. G. Glabe, D. H. Cribbs, et al.
Anti-Abeta1 11 Antibody Binds to Different beta-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers
J. Biol. Chem.,
August 3, 2007;
282(31):
22376 - 22386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mouri, Y. Noda, H. Hara, H. Mizoguchi, T. Tabira, and T. Nabeshima
Oral vaccination with a viral vector containing A{beta} cDNA attenuates age-related A{beta} accumulation and memory deficits without causing inflammation in a mouse Alzheimer model
FASEB J,
July 1, 2007;
21(9):
2135 - 2148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Prada, M. Garcia-Alloza, R. A. Betensky, S. X. Zhang-Nunes, S. M. Greenberg, B. J. Bacskai, and M. P. Frosch
Antibody-Mediated Clearance of Amyloid-{beta} Peptide from Cerebral Amyloid Angiopathy Revealed by Quantitative In Vivo Imaging
J. Neurosci.,
February 21, 2007;
27(8):
1973 - 1980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. V. Nikolic, Y. Bai, D. Obregon, H. Hou, T. Mori, J. Zeng, J. Ehrhart, R. D. Shytle, B. Giunta, D. Morgan, et al.
Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage
PNAS,
February 13, 2007;
104(7):
2507 - 2512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Levites, K. Jansen, L. A. Smithson, R. Dakin, V. M. Holloway, P. Das, and T. E. Golde
Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid beta, Amyloid beta40, and Amyloid beta42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice.
J. Neurosci.,
November 15, 2006;
26(46):
11923 - 11928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Masters and K. Beyreuther
Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway
Brain,
November 1, 2006;
129(11):
2823 - 2839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang
Therapeutic approaches to Alzheimer's disease
Brain,
November 1, 2006;
129(11):
2840 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Patton, W. M. Kalback, C. L. Esh, T. A. Kokjohn, G. D. Van Vickle, D. C. Luehrs, Y.-M. Kuo, J. Lopez, D. Brune, I. Ferrer, et al.
Amyloid-{beta} Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients: A Biochemical Analysis
Am. J. Pathol.,
September 1, 2006;
169(3):
1048 - 1063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Wilcock, J. Alamed, P. E. Gottschall, J. Grimm, A. Rosenthal, J. Pons, V. Ronan, K. Symmonds, M. N. Gordon, and D. Morgan
Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice.
J. Neurosci.,
May 17, 2006;
26(20):
5340 - 5346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Maier, T. J. Seabrook, N. D. Lazo, L. Jiang, P. Das, C. Janus, and C. A. Lemere
Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
J. Neurosci.,
May 3, 2006;
26(18):
4717 - 4728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Dickstein, K. E. Biron, M. Ujiie, C. G. Pfeifer, A. R. Jeffries, and W. A. Jefferies
A{beta} peptide immunization restores blood-brain barrier integrity in Alzheimer disease
FASEB J,
March 1, 2006;
20(3):
426 - 433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Robbins, R. A. Betensky, S. B. Domnitz, S. M. Purcell, M. Garcia-Alloza, C. Greenberg, G. W. Rebeck, B. T. Hyman, S. M. Greenberg, M. P. Frosch, et al.
Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease
J. Neurosci.,
January 11, 2006;
26(2):
365 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
